MARCKSL1

Across TCGA pan-cancer cohorts, MARCKSL1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MARCKSL1 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MARCKSL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MARCKSL1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where MARCKSL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.381	0.951	.006	9	view →
CCRCC	DFS	Quartile	III,IV	0.864	0.370	.016	7	view →
LSCC	OS	Median	II,III,IV	0.947	0.765	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MARCKSL1–PDAC (OS)

Open the PDAC breakdown →